

The increased ratio of Treg/Th2 in promoting metastasis of hepatocellular carcinoma

El aumento de la proporción de Treg/Th2 en la promoción de la metástasis del carcinoma hepatocelular

Chuanzhi Li, Shuying Li, Jing Zhang, and Fenglei Sun*

Department of Hepatobiliary and Pancreatic Surgery, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong, China

Abstract

Objective: Liver cancer is the fifth most common cancer in the world. Research on the pathogenesis and detailed molecular mechanisms of liver cancer is very important. The immune system plays an important role in regulating the incidence and metastasis of liver cancer. **Materials and methods:** This work collected 20 blood samples from patients with clinical hepatocellular carcinoma without metastasis, 20 blood samples from patients with metastatic hepatocellular carcinoma, and 20 blood samples from healthy subjects. Flow cytometry was used to analyze the content of Treg and Th2 cells in the three groups of blood samples. Immunofluorescence was applied to analyze the relative expression of CTLA-4 and CD28 in lymphocytes of each group of blood samples. Western blot was used to analyze the T cell surface protein CTLA-4, CD28, GATA3, and FOXP3 expression in each group of blood samples. **Results:** The expression of CD28 and GATA3 in the blood of patients with hepatocellular carcinoma without metastasis was obviously higher than that of patients with metastasis of hepatocellular carcinoma, which is contrary to the expression trend of CTLA-4 and FOXP3, and corresponds to the content ratio of Treg and Th2 cells, thus verifying the relationship between Treg/Th2 ratio and metastasis of hepatocellular carcinoma. **Conclusions:** In the micro-environment of liver cancer, the ratio of Treg/Th2 will increase significantly, thereby promoting the metastasis of hepatocellular carcinoma.

Keywords: Hepatocellular carcinoma. Treg cells. Th2 cells. CTLA-4. CD28.

Resumen

Objetivo: El cáncer de hígado es el quinto cáncer más común en el mundo. La investigación sobre la patogenia y los mecanismos moleculares detallados del cáncer de hígado es muy importante. El sistema inmunológico juega un papel importante en la regulación de la incidencia y metástasis del cáncer de hígado. **Material y métodos:** Este trabajo recogió 20 muestras de sangre de pacientes con carcinoma hepatocelular clínico sin metástasis, 20 muestras de sangre de pacientes con carcinoma hepatocelular metastásico y 20 muestras de sangre de sujetos sanos. Se utilizó citometría de flujo para analizar el contenido de células Treg y Th2 en los tres grupos de muestras de sangre. Se aplicó inmunofluorescencia para analizar la expresión relativa de CTLA-4 y CD28 en linfocitos de cada grupo de muestras de sangre. Se utilizó Western blot para analizar la expresión de la proteína de superficie de células T CTLA-4, CD28, GATA3, FOXP3 en cada grupo de muestras de sangre. **Resultados:** La expresión de CD28 y GATA3 en la sangre de pacientes con carcinoma hepatocelular sin metástasis fue obviamente mayor que la de pacientes con metástasis de carcinoma hepatocelular, lo cual es contrario a la tendencia de

*Correspondence:

Fenglei Sun

E-mail: flei_s0723@126.com

Date of reception: 21-04-2021

Date of acceptance: 06-07-2021

DOI: 10.24875/CIRUE.M21000473

Cir Cir (Eng). 2022;90(2):185-190

Contents available at PubMed

www.cirugiaycirujanos.com

2444-0507/© 2021 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

expresión de CTLA-4 y FOXP3, y corresponde al contenido relación de células Treg y Th2, verificando así la relación entre la relación Treg/Th2 y la metástasis del carcinoma hepatocelular. Conclusiones: En el microambiente del cáncer de hígado, la proporción de Treg/Th2 aumentará significativamente, promoviendo así la metástasis del carcinoma hepatocelular.

Palabras clave: Carcinoma hepatocelular. Células Treg; Células Th2. CTLA-4. CD28.

Introduction

Liver cancer is the fifth most common cancer in the world, and liver cancer is the main cause of death in patients with liver cirrhosis^{1,2}. Hepatocellular carcinoma is one of the common malignant tumors in our country, with a high incidence in the southeast coastal areas. The median age of liver cancer patients in our country is 40-50 years old, and it is more common in men than women. Under normal circumstances, the immune system can recognize and eliminate tumor cells in the tumor microenvironment. However, to survive and grow, tumor cells can adopt different strategies to suppress the body's immune system and not be killed normally³. Therefore, research on the pathogenesis and detailed molecular mechanisms of liver cancer is very important, and research in this area has been a hot spot for many years⁴.

Regulatory T cells (Tregs) are a type of T cell subgroup that controls autoimmune reactivity in the body and were also called suppressor T cells in the early stage⁵. Regulatory T cells are one of the important factors for maintaining immune tolerance of the body. They are secreted by thymus, exported to the periphery, and inhibit the potential self-reactivity existing in the normal body through active regulation. The activation and proliferation of T cells regulate the body's immunity^{6,7}. At present, the immunosuppressive function of tumor-related Treg cells is the main obstacle to improving the effectiveness of immunotherapy⁸.

T helper2 cell (Th2) is a subset of T cells that can secrete Th2-type cytokines (such as interleukins [IL-4], IL-5, IL-10, and IL-13). These cytokines can promote the proliferation of Th2 cells and inhibit the proliferation of Th1 cells, and, at the same time, assist B cell activation and exert humoral immunity⁹. T helper cells play a central role in the regulation of immune responses. In addition to effector cells, Th cells are also regulated by regulatory T cells¹⁰.

Cytotoxic T Lymphocyte Associated Protein-4 (CTLA-4) is a protein receptor that acts as an immune checkpoint and downregulates the immune response. CTLA-4 is constitutively expressed in

regulatory T cells but is only upregulated in conventional T cells after activation and this phenomenon is particularly pronounced in cancer¹¹. When it binds to CD80 or CD86 on the surface of antigen presenting cells, it acts as a "off" switch. CTLA-4 is the target gene of the transcription factor Forkhead Box P3 (FOXP3) and a protein on the surface of T lymphocytes, which plays an important role in down-regulating the immune response¹². CD28 is a specific glycoprotein on the surface of T cells, involved in inducing T cell activation, T cell proliferation and cytokine production, and promoting T cell survival¹³.

Both CD28 and CTLA-4 can bind ligands CD80 and CD86 to regulate the function of T cells. Therefore, in the liver cancer microenvironment, the balance between the expression of CTLA-4 and CD28 on the surface of T cells determines the immune surveillance of T cells¹⁴.

This work collected 20 blood samples from patients with clinical hepatocellular carcinoma without metastasis, 20 blood samples from patients with metastatic hepatocellular carcinoma, and 20 blood samples from healthy subjects. Flow cytometry (FCM) was used to analyze the content of Tregs and Th2 cells in each group of blood samples. Immunofluorescence was used to analyze the relative expression of CTLA-4 and CD28 in lymphocytes of each group of blood samples. Western blot was used to analyze the T cell surface protein CTLA-4, CD28, GATA-binding protein 3 (GATA3), FOXP3 expression in each group of blood samples.

Materials and methods

Experiment design

Twenty blood samples were collected from patients with clinical hepatocellular carcinoma without metastasis (Ca-N-M), 20 blood samples from patients with metastatic hepatocellular carcinoma (Ca-M), and 20 blood samples from healthy subjects (NC). The content of Treg and Th2 cells in each group of blood samples was detected by FCM. The relative expression of CTLA-4 and

CD28 in lymphocytes of each group of blood samples were analyzed by immunofluorescence technology. Finally, the expression of T cell surface proteins CTLA-4, CD28, GATA3, and FOXP3 in each group of blood samples was determined by Western Blot analysis.

FCM analysis

The single cell suspension was added to a 2 ml centrifuge tube, centrifuged at 1500 rpm for 5 min, and the supernatant was discarded. Use 4% paraformaldehyde (PFA) to fix at 4°C for 30 min, and then use 0.1% Triton X-100 to fix at room temperature for 10 min. Add 200 μ l of the primary antibody diluted with PBA, incubate at 4°C for 2 h, then centrifuge to remove the supernatant and wash with PBS. Add 200 μ l of fluorescein-labeled secondary antibody diluted with PBA, and incubate for 30 min at 4°C in the dark. Finally, the cells were re-suspended in 500 μ l PBS, placed in a flow tube, and detected by FCM.

Immunofluorescence analysis

Select the appropriate fluorescein-labeled antibody to stain CTLA-4 and CD28 in the lymphocytes of each group of blood samples, and then use DAPI to stain the nuclei in dark environment and observe through a fluorescence microscope.

Western blot analysis

Collect T cells from each blood sample group, and add 200 μ l of cell lysate to each six-well plate. After sonication, the cells were lysed on ice for 1 h. The lysed cell sample was centrifuged at 12,500 rpm for 15 min at 4°C. Then, transfer the supernatant in the centrifuge tube to a clean centrifuge tube. BCA protein quantification kit was used to quantify protein concentration. The measured protein samples were stored at -80°C. In Western blot electrophoresis, the protein loading concentration was 50 μ g per well. After SDS-PAGE electrophoresis, the membrane was transferred and blocked. CTLA-4, CD28, GATA3, FOXP3, and B-actin (1: 500, anti-human, Abcam, USA) primary antibody were diluted to the concentration which can be used. The samples were incubated overnight on a shaker at 4°C. After washing with PBS, the samples were incubated with the secondary antibody (1: 1000, anti-human, Abcam, USA) for 30 min at room temperature in the dark. Finally, the developer was used for development and photography.

Statistical analysis

The experimental results are expressed as mean $\pm$ standard deviation. Statistical analysis was performed using SPSS 22.0 software. The figures were produced with Origin 2020 software.

Results

The content of Treg and Th2 cells

The data obtained by FCM showed that the content of Treg and Th2 cells showed different trends among the three groups. The content of Treg cells in the three groups from large to small was Ca-M group, Ca-N-M group, and NC group. The content of Th2 cells in the three groups from large to small was Ca-N-M group, Ca-M group, and NC group (Fig. 1).

Relative expression of CD28 and CTLA-4

Immunofluorescence analysis technology was used to determine the relative expression of CTLA-4 and CD28 in lymphocytes of each blood sample group, and the results are shown in figure 2. It can be seen from the figure that the relative expression of CTLA-4 in Ca-M group is higher than that in Ca-N-M group, while the expression in Ca-N-M group is higher than NC group. For CD28, the relative expression in Ca-M group is lower than Ca-N-M group and at the same time higher than NC group.

The expression level of CD28, CTLA-4, GATA3, and FOXP3

The expression level of CD28, CTLA-4, GATA3, and FOXP3 was obtained from Western blot analysis. B-actin was the internal reference protein in this Western blot analysis experiment (Fig. 3). For Ca-N-M group compared to NC group, the expression level of CTLA-4 and FOXP3 is higher, while that of CD28 and GATA3 are much higher. For Ca-M group, the expression level of CD28 and GATA3 is higher than that of NC group, and while that of CTLA-4 and FOXP3 is much higher.

Discussion

For Tc and Th cells, costimulatory signal transduction lowers the threshold of T cell activation and promotes the proliferation and differentiation of T cells. In the




Figure 1. The flow cytometry results of The content of Treg and Th2 cells. The data of NC group are all equivalent to that of healthy people. **A:** Treg cells (first row) and Th2 cells (second row) of NC, Ca-N-M, and Ca-M group. **B:** the percentage of target cells (Treg and Th2 cells) in total cells. The symbol ** means $p < 0.01$, *** means $p < 0.001$, **** means $p < 0.0001$ (compared to the NC group).

absence of CD28 co-stimulation, naive T cells will not be activated and will not respond¹⁵. The co-stimulation of CD28 has many important molecular effects: 1. Induces the expression of IL-2 receptor (IL-2R) on the surface of T cells, thereby allowing cells to receive the third signal; 2. Make Th cells begin to secrete a large number of cells Factors and chemokines; and 3. Induces and upregulates the expression of other co-stimulatory and regulatory molecules in Th and Tc cells^{16,17}.

CTLA4 is homologous to the T cell costimulatory protein CD28, and these two molecules, respectively, bind to CD80 and CD86 (also known as B7-1 and B7-2) on antigen presenting cells. Compared with CD28, CTLA-4 has a higher affinity for CD80 and CD86, which makes it perform better than CD28 ligand. CTLA4 transmits inhibitory signals to T cells, while CD28 transmits stimulation signals¹⁸. CTLA4 is also present in regulatory T cells (Treg cells), which contributes to its inhibitory function. T cell activation through T cell receptors and CD28 leads to the increased expression of CTLA-4¹⁹.

FOXP3 is a member of the fork-head transcription factor family and is considered to be a marker molecule of regulatory T cells (Treg)^{20,21}. Mutations of FOXP3 gene can cause serious autoimmune diseases. Therefore, FOXP3 plays a key role in regulating the body's immune stability. As a transcriptional regulatory factor, FOXP3 regulates the activity of Treg by directly

regulating a variety of genes²². FOXP3 cannot only be used as a marker molecule of CD+4T and CD+25T cells, but also a key factor that determines the function of CD+4T and CD+25T cells. FOXP3 secretes TGF- β and IL-10 for CD-127T, CD+4T, and CD+25T cells, which two are related to its immunoregulatory function²³.

The transcription factor GATA3 is a key factor regulating cell differentiation and cytokine expression and is a specific transcription factor for Th2 cells²⁴. Th2 cells express IL-4, IL-5, IL-13, and other cytokines, promote the production of antibodies, mediate humoral immune response, fight against pathogens outside the cell, and inhibit the function of anti-tumor immunity. GATA3 is critical in regulating the expression of cytokines in T cells and is limited in the expression of Th2 cells²⁵.

Conclusions

CTLA-4, CD28, GATA3, and FOXP3 are all critical factors in regulating the expression level of Treg and Th2 cells. The expression of CD28 and GATA3 in the blood of patients with hepatocellular carcinoma without metastasis is obviously higher than that of patients with metastasis of hepatocellular carcinoma, which is contrary to the expression trend of CTLA-4 and FOXP3 and corresponds to the content ratio of Treg and Th2 cells, thus verifying the relationship between




Figure 2. The immunofluorescence results of relative expression of CTLA-4 and CD28. All pictures have the same magnification scale, and the scale bar is shown in **A**. the average fluorescence intensity was calculated by the software ImageJ. The data of NC group are all equivalent to that of healthy people. **A:** relative expression of CTLA-4 in NC, Ca-N-M, and Ca-M group. **B:** relative expression of CD28 in NC, Ca-N-M, and Ca-M group. **C:** the average fluorescence intensity of CTLA-4 (Red) in three groups. **D:** the average fluorescence intensity of CD28 (Red) in three groups. The symbol * means $p < 0.05$, ** means $p < 0.01$, *** means $p < 0.001$ (compared to the NC group).




Figure 3. The Western blot analysis results of protein CTLA-4, CD28, GATA3, and FOXP3. The data of NC group are all equivalent to that of healthy people. **A:** original gel electrophoresis image. **B-F:** the ratio of protein CTLA-4, CD28, GATA3, and FOXP3 expression compared to NC group. The symbol ** means $p < 0.01$, *** means $p < 0.001$ (compared to the NC group).

Treg/Th2 ratio and metastasis of hepatocellular carcinoma. The results indicate that in the microenvironment of hepatocellular carcinoma, the ratio of Treg/Th2 will increase significantly, thereby promoting the metastasis of hepatocellular carcinoma.

Acknowledgments

The authors would like to acknowledge everyone for their helpful contributions in this paper.

Funding

The authors declare that there was no funding provided for this paper.

Conflicts of interest

The authors declared that they have no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

References

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet*. 2012;379:1245-55.
2. European Assoc Study Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018;69:182-236.
3. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. *Surg Oncol Clin N Am*. 2015;24:1-17.
4. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. *Gut*. 2014;63:844-55.
5. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity*. 2014;40:569-81.
6. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of Treg-mediated T cell suppression. *Front Immunol*. 2012;3:51.
7. di Pilato M, Kim EY, Cadilha BL, Prüßmann JN, Nasrallah MN, Seruggia D, et al. Targeting the CBM complex causes T-reg cells to prime tumours for immune checkpoint therapy. *Nature*. 2019;570:112-6.
8. Yu S, Wang Y, Hou J, Li W, Wang X, Xiang L, Guo H. Tumor-infiltrating immune cells in hepatocellular carcinoma: tregs is correlated with poor overall survival. *PLoS One*. 2020;15:e0231003.
9. Chen T, Chen Y, Bao W, Lu W. T-lymphocyte subsets and Th1/Th2 cytokines in convalescent patients with Epstein-Barr virus-associated aplastic anemia. *Hematology*. 2020;25:11-6.
10. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory t-cell paradigm in pregnancy. *Am J Reprod Immunol*. 2010;63:601-10.
11. Fiegler E, Doleschel D, Koletnik S, Rix A, Weiskirchen R, Borkham-Kamphorst E, et al. Dual CTLA-4 and PD-L1 blockade inhibits tumor growth and liver metastasis in a highly aggressive orthotopic mouse model of colon cancer. *Neoplasia*. 2019;21:932-44.
12. Liu Q, Du F, Huang W, Ding X. Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma. *Aging (Albany NY)*. 2019;11:2343-51.
13. Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, et al. PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. *Immunity*. 2019;51:1059.
14. Takami M, Cunha C, Motohashi S, Nakayama T, Iwashima M. TGF-beta suppresses RasGRP1 expression and supports regulatory T cell resistance against p53-induced CD28-dependent T-cell apoptosis. *Eur J Immunol*. 2018;48:1938-43.
15. Hodge G, Hodge S. Steroid resistant CD8(+)CD28(null) NKT-like pro-inflammatory cytotoxic cells in chronic obstructive pulmonary disease. *Front Immunol*. 2016;7:617.
16. Olive D. Functions of CD28, CTLA-4 and PD-1. *Bull Cancer*. 2018;105:S3-15.
17. Su YR, Chen MT, Xiong K, Bai L. Endogenous toll-like receptor 2 modulates Th1/Treg-promoting dendritic cells in mice corneal transplantation model. *Curr Eye Res*. 2019;45:774-81.
18. Lo B, Abdel-Motal UM. Lessons from CTLA-4 deficiency and checkpoint inhibition. *Curr Opin Immunol*. 2017;49:14-9.
19. Zhang S, Yang X, Wang W. Associations of polymorphisms in CTLA-4 and IL-18 with liver diseases: evidence from a meta-analysis. *Biosci Rep*. 2019. In press. doi: <https://doi.org/10.1042/BSR20193518>
20. Hamilton BK, Do J, Min B. IL-27 enhances inducible foxp3+treg function to prevent acute graft-versus-host disease lethality. *Blood*. 2016;128:3343.
21. Mathies F, Steffens N, Kleinschmidt D. Colitis promotes a pathological condition of the liver in the absence of foxp3(+) regulatory T cells. *J Immunol*. 2018;201:3558-68.
22. Wu X, Xue R, Peng H, Gan X, Lu X, Yan, W, et al. Traf6 inhibitor boosts antitumor immunity by impeding regulatory T cell migration in Hepa1-6 tumor model. *Int Immunopharmacol*. 2019;77:105965.
23. da Motta RJ, Almeida LY, Villafuerte KR, Ribeiro-Silva A, Leon JE, Tirapelli C. FOXP3+and CD25+cells are reduced in patients with stage IV, grade C periodontitis: a comparative clinical study. *J Periodontal Res*. 2020;55:374-80.
24. Nakamura A, Takahashi D, Nakamura Y, Yamada T, Matsumoto M, Hase K. Polyamines polarized Th2/Th9 cell-fate decision by regulating GATA3 expression. *Arch Biochem Biophys*. 2020;693:108587.
25. Zhu JF. GATA3 regulates the development and functions of innate lymphoid cell subsets at multiple stages. *Front Immunol*. 2017;8:1571.